• SHARE

Growing worries that AstraZeneca PLC’s COVID-19 vaccine causes rare blood clots could hinder immunization campaigns across the world, from London to Seoul.

Reviews by U.K. and European Union regulators finding potential links to the unusual side effects are another blow for the shot, a cheaper and easier-to-deploy product that many nations are counting on in a bid to end the pandemic.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)